Skip to Content
Merck

R116

Riluzole

≥98% (HPLC), solid, glutamate release inhibitor

Synonym(s):

2-Amino-6-(trifluoromethoxy)benzothiazole

Slide 1 of 4
Sign In to View Organizational & Contract Pricing.

Select a Size

25 MG

1 320,00 kr

250 MG

8 510,00 kr

500 MG

12 110,00 kr

1 320,00 kr

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C8H5F3N2OS
CAS Number:
1744-22-5
Molecular Weight:
234.20
UNSPSC Code:
12352200
PubChem Substance ID:
24278006
NACRES:
NA.77
MDL number:
MFCD00210213

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Riluzole, solid

SMILES string

Nc1nc2ccc(OC(F)(F)F)cc2s1

InChI

1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

InChI key

FTALBRSUTCGOEG-UHFFFAOYSA-N

form

solid

originator

Sanofi Aventis

Quality Level

100

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scnn1g(24768)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
557324PHR24991604337
Riluzole solid

Sigma-Aldrich

R116

Riluzole

Riluzole A cell-permeable benzothiazole compound that potently inhibits glutamate release and blocks Na+ channels.

Sigma-Aldrich

557324

Riluzole

Riluzole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2499

Riluzole

Riluzole United States Pharmacopeia (USP) Reference Standard

USP

1604337

Riluzole

form

solid

form

solid

form

solid

form

-

Quality Level

100

Quality Level

100

Quality Level

300

Quality Level

-

originator

Sanofi Aventis

originator

-

originator

-

originator

-

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scnn1g(24768)

Gene Information

-

Gene Information

-

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

Biochem/physiol Actions

Glutamate release inhibitor; anticonvulsant

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H300

Hazard Classifications

Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000454119
0000454119
0000443050
0000443049
0000443048

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryan S Phillips et al.
eLife, 11 (2022-07-08)
Previously our computational modeling studies (Phillips et al., 2019) proposed that neuronal persistent sodium current (INaP) and calcium-activated non-selective cation current (ICAN) are key biophysical factors that, respectively, generate inspiratory rhythm and burst pattern in the mammalian preBötzinger complex (preBötC)
Diana S L Chow et al.
Journal of neurosurgery. Spine, 17(1 Suppl), 129-140 (2012-09-19)
The aim of this paper was to characterize individual and population pharmacokinetics of enterally administered riluzole in a Phase 1 clinical trial of riluzole as a neuroprotective agent in adults 18-70 years old with acute spinal cord injury (SCI). Thirty-five
Arun Pal et al.
Life science alliance, 7(8) (2024-05-18)
Amyotrophic lateral sclerosis (ALS) leads to death within 2-5 yr. Currently, available drugs only slightly prolong survival. We present novel insights into the pathophysiology of Superoxide Dismutase 1 (SOD1)- and in particular Fused In Sarcoma (FUS)-ALS by revealing a supposedly
Steve Vucic et al.
Brain : a journal of neurology, 136(Pt 5), 1361-1370 (2013-04-26)
Riluzole, a benzothiazole derivative, has been shown to be effective in prolonging survival in amyotrophic lateral sclerosis. The mechanisms by which riluzole exerts neuroprotective effects in amyotrophic lateral sclerosis remains to be fully elucidated, although inhibition of glutamatergic transmission and
Martina Janikova et al.
Biomolecules, 11(7) (2021-08-07)
Chronic sensitization to serotonin 1A and 7 receptors agonist 8-OH-DPAT induces compulsive checking and perseverative behavior. As such, it has been used to model obsessive-compulsive disorder (OCD)-like behavior in mice and rats. In this study, we tested spatial learning in
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service